Catabasis Pharma (CATB) Misses Q1 EPS by 9c

Catabasis Pharma (NASDAQ: CATB) reported Q1 EPS of ($0.29), $0.09 worse than the analyst estimate of ($0.20).

“We are pleased to see additional positive clinical data from our MoveDMD trial early in 2018 that continue to demonstrate the potential of edasalonexent as a disease-modifying therapy for all patients affected by Duchenne, regardless of mutation. As evidenced by sustained improvements in all assessments of physical function and in biomarkers of muscle health and inflammation, edasalonexent has slowed the progression of Duchenne in the MoveDMD trial,” said Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. “We believe that these effects ultimately will translate to boys with Duchenne maintaining functional abilities longer.”

For earnings history and earnings-related data on Catabasis Pharma (CATB) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c